A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)

Thomas Cash, Elizabeth Fox, Xiaowei Liu, Charles G. Minard, Joel M. Reid, Adrienne C. Scheck, Brenda J. Weigel, Cynthia Wetmore

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases